Cargando…

Three-year results of accelerated transepithelial cross-linking (30 mW/cm(2) × 3 min) for keratoconus: a prospective study

OBJECTIVE: To assess the long-term efficacy and safety of accelerated transepithelial corneal cross-linking (ATE-CXL) with 30 mW/cm(2) × 3 min. METHODS AND ANALYSIS: Thirty-four eyes of 23 patients with progressive keratoconus (KCN) recruited within a single centre were enrolled in this prospective...

Descripción completa

Detalles Bibliográficos
Autores principales: Ishii, Hitoha, Yoshida, Junko, Toyono, Tetsuya, Yamagami, Satoru, Usui, Tomohiko, Miyai, Takashi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8830257/
https://www.ncbi.nlm.nih.gov/pubmed/35224204
http://dx.doi.org/10.1136/bmjophth-2021-000827
_version_ 1784648236489768960
author Ishii, Hitoha
Yoshida, Junko
Toyono, Tetsuya
Yamagami, Satoru
Usui, Tomohiko
Miyai, Takashi
author_facet Ishii, Hitoha
Yoshida, Junko
Toyono, Tetsuya
Yamagami, Satoru
Usui, Tomohiko
Miyai, Takashi
author_sort Ishii, Hitoha
collection PubMed
description OBJECTIVE: To assess the long-term efficacy and safety of accelerated transepithelial corneal cross-linking (ATE-CXL) with 30 mW/cm(2) × 3 min. METHODS AND ANALYSIS: Thirty-four eyes of 23 patients with progressive keratoconus (KCN) recruited within a single centre were enrolled in this prospective interventional study. Exclusion criteria included: history of Descemet’s membrane rupture, glaucoma, uveitis, severe dry eye, concurrent corneal infections, and systemic disease that could affect corneal healing. ATE-CXL was performed with 3 min of ultraviolet-A continuous irradiation (30 mW/cm(2)). Follow-up examinations were scheduled on postoperative day 1; 1 and 2 weeks; 1, 3 and 6 months; and 1, 2 and 3 years. Main outcome measures were maximum corneal power (Kmax), average corneal power (AvgK), steepest corneal power (Ks), central corneal thickness, thinnest corneal thickness, uncorrected visual acuity (UCVA), best spectacle-corrected visual acuity (BCVA) and endothelial cell density. RESULTS: Mean Kmax, AvgK, Ks, UCVA, BCVA and endothelial cell density did not significantly change over 3 years. The speed of progression obtained by linear regression analysis on corneal parameters (Kmax, AvgK, Ks) improved after ATE-CXL. All baseline parameters correlated with the postoperative Kmax slope. Two eyes underwent ATE-CXL redo because of continued progression after the primary CXL. CONCLUSION: This is the first report of 3-year results of ATE-CXL with 30 mW/cm(2) × 3 min. ATE-CXL (30 mW/cm(2) × 3 min) was safe and effective for slowing down KCN progression. TRIAL REGISTRATION NUMBER: This study was registered with ID UMIN000009372 in UMIN-Clinical Trials Registry.
format Online
Article
Text
id pubmed-8830257
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-88302572022-02-24 Three-year results of accelerated transepithelial cross-linking (30 mW/cm(2) × 3 min) for keratoconus: a prospective study Ishii, Hitoha Yoshida, Junko Toyono, Tetsuya Yamagami, Satoru Usui, Tomohiko Miyai, Takashi BMJ Open Ophthalmol Cornea and Ocular Surface OBJECTIVE: To assess the long-term efficacy and safety of accelerated transepithelial corneal cross-linking (ATE-CXL) with 30 mW/cm(2) × 3 min. METHODS AND ANALYSIS: Thirty-four eyes of 23 patients with progressive keratoconus (KCN) recruited within a single centre were enrolled in this prospective interventional study. Exclusion criteria included: history of Descemet’s membrane rupture, glaucoma, uveitis, severe dry eye, concurrent corneal infections, and systemic disease that could affect corneal healing. ATE-CXL was performed with 3 min of ultraviolet-A continuous irradiation (30 mW/cm(2)). Follow-up examinations were scheduled on postoperative day 1; 1 and 2 weeks; 1, 3 and 6 months; and 1, 2 and 3 years. Main outcome measures were maximum corneal power (Kmax), average corneal power (AvgK), steepest corneal power (Ks), central corneal thickness, thinnest corneal thickness, uncorrected visual acuity (UCVA), best spectacle-corrected visual acuity (BCVA) and endothelial cell density. RESULTS: Mean Kmax, AvgK, Ks, UCVA, BCVA and endothelial cell density did not significantly change over 3 years. The speed of progression obtained by linear regression analysis on corneal parameters (Kmax, AvgK, Ks) improved after ATE-CXL. All baseline parameters correlated with the postoperative Kmax slope. Two eyes underwent ATE-CXL redo because of continued progression after the primary CXL. CONCLUSION: This is the first report of 3-year results of ATE-CXL with 30 mW/cm(2) × 3 min. ATE-CXL (30 mW/cm(2) × 3 min) was safe and effective for slowing down KCN progression. TRIAL REGISTRATION NUMBER: This study was registered with ID UMIN000009372 in UMIN-Clinical Trials Registry. BMJ Publishing Group 2022-02-08 /pmc/articles/PMC8830257/ /pubmed/35224204 http://dx.doi.org/10.1136/bmjophth-2021-000827 Text en © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Cornea and Ocular Surface
Ishii, Hitoha
Yoshida, Junko
Toyono, Tetsuya
Yamagami, Satoru
Usui, Tomohiko
Miyai, Takashi
Three-year results of accelerated transepithelial cross-linking (30 mW/cm(2) × 3 min) for keratoconus: a prospective study
title Three-year results of accelerated transepithelial cross-linking (30 mW/cm(2) × 3 min) for keratoconus: a prospective study
title_full Three-year results of accelerated transepithelial cross-linking (30 mW/cm(2) × 3 min) for keratoconus: a prospective study
title_fullStr Three-year results of accelerated transepithelial cross-linking (30 mW/cm(2) × 3 min) for keratoconus: a prospective study
title_full_unstemmed Three-year results of accelerated transepithelial cross-linking (30 mW/cm(2) × 3 min) for keratoconus: a prospective study
title_short Three-year results of accelerated transepithelial cross-linking (30 mW/cm(2) × 3 min) for keratoconus: a prospective study
title_sort three-year results of accelerated transepithelial cross-linking (30 mw/cm(2) × 3 min) for keratoconus: a prospective study
topic Cornea and Ocular Surface
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8830257/
https://www.ncbi.nlm.nih.gov/pubmed/35224204
http://dx.doi.org/10.1136/bmjophth-2021-000827
work_keys_str_mv AT ishiihitoha threeyearresultsofacceleratedtransepithelialcrosslinking30mwcm23minforkeratoconusaprospectivestudy
AT yoshidajunko threeyearresultsofacceleratedtransepithelialcrosslinking30mwcm23minforkeratoconusaprospectivestudy
AT toyonotetsuya threeyearresultsofacceleratedtransepithelialcrosslinking30mwcm23minforkeratoconusaprospectivestudy
AT yamagamisatoru threeyearresultsofacceleratedtransepithelialcrosslinking30mwcm23minforkeratoconusaprospectivestudy
AT usuitomohiko threeyearresultsofacceleratedtransepithelialcrosslinking30mwcm23minforkeratoconusaprospectivestudy
AT miyaitakashi threeyearresultsofacceleratedtransepithelialcrosslinking30mwcm23minforkeratoconusaprospectivestudy